

## **SAFETY DATA SHEET**

Section 1: Identification					
Material	Lacosamide Tablets USP				
Manufacturer	Annora Pharma Private Limited, Survey No. 261, Annaram Village,				
	Gummadidala Mandal, Sangareddy, Telangana 502313, India (IND)				
Distributor	Camber Pharmaceuticals, Inc., Piscataway, NJ 08854				
Section 2: Hazard(s) Identification					
Hazard statements	Causes serious eye irritation.				
	Wash thoroughly after handling.				
	Do not eat, drink or smoke when using this product.				
	Wear eye protection / face protection.				
Section 3: Composition/Information on Ingredients					
Ingredients	Lacosamide				
CAS	175481-36-4				
Section 4: First-Aid Measures					
Inhalation	In case of unconsciousness place patient stably in side position for transportation				
Skin Contact	Immediately wash with water and soap and rinse thoroughly.				
Eye Contact	Rinse opened eye for several minutes under running water.				
General information	If symptoms persist, consult a doctor.  Immediately remove any clothing soiled by the product. In case of				
irregular breathing or respiratory arrest provide artificial respiration.					
	Section 5: Fire-Fighting Measures				
<b>Extinguishing Media (Suitable)</b>	Use firefighting measures that suit the environment. A solid water stream may be inefficient.				
<b>Special Firefighting Procedures</b>	No further relevant information available.				
Protective equipment	No special measures required.				
Section 6: Accidental Release Measures					
Clean-up Methods	Absorb with liquid-binding material (sand, diatomite, acid binders,				
	universal binders, sawdust). Dispose contaminated material as waste according to local regulations.				
Personal Precautions:	Wear protective equipment. Keep unprotected persons away.				
<b>Environmental Precautions:</b>	Do not allow to enter sewers /surface or ground floor.				
Section 7: Handling and Storage					
Handling:	No special precautions are necessary if used correctly.				



Storage:	As per package insert label.					
Information about protection against explosions and fires	No special measures required.					
Section 8: Exposure Controls/Personal Protection						
Personal Protective Equipment: General protective and hygienic measures	Keep away from foodstuffs, beverages and feed. Immediately remove all soiled and contaminated clothing. Wash hands before breaks and at the end of work Avoid contact with the eyes and skin					
Breathing equipment	Not required					
Protection of hands	The glove material has to be impermeable and resistant to the product /the substance/the preparation. Due to missing tests no recommendation to the glove material can be given for the product/the preparation /the chemical mixture. Selection of the glove material on consideration of the penetration times, rates of diffusion and the degradation.					
Material of gloves	The selection of the suitable gloves does not only depend on the material, but also on further marks of quality and varies from manufacturer to manufacturer.					
Penetration time of glove material	The exact break through time has to be found out by the manufacturer of the protective gloves and has to be observed.					
Sec	Section 9: Physical and Chemical Properties					
Physical Form	Tablet					
Description	biconvex, film-coated tablets, deb the other side. They are supplied as Bottle of 60 Tablets Bottle of 180 Tablets Bottle of 500 Tablets Blister pack of 100 (10 x 10s) Unit dose tablets (Alu-Alu) Lacosamide Tablets USP, 100 biconvex, film-coated tablets, deb the other side. They are supplied as	NDC 31722-812-60 NDC 31722-812-18 NDC 31722-812-05 NDC 31722-812-32 mg are yellow colored, oval shaped, possed with 'J' on one side and '13' on				
		NDC 31722-813-60 NDC 31722-813-18 NDC 31722-813-05 NDC 31722-813-32 mg are salmon colored, oval shaped, ossed with 'J' on one side and '14' on s follows: NDC 31722-814-60 NDC 31722-814-18 NDC 31722-814-05 NDC 31722-814-32				



	Lacosamide Tablets USP, 200 mg are blue colored, oval shaped,				
	biconvex, film-coated tablets, debossed with 'J' on one side and '15' on				
	the other side. They are supplied as follows:				
	Bottle of 60 Tablets NDC 31722-815-60				
	Bottle of 180 Tablets NDC 31722-815-18				
	Bottle of 500 Tablets NDC 31722-815-05				
	Blister pack of 100 (10 x 10s) Unit dose tablets (Alu-Alu) NDC 31722-815-32				
Section 10: Stability and Reactivity					
Thermal decomposition/ conditions to be avoided	No decomposition if used according to specifications				
Conditions to avoid	No further relevant information available.				
Incompatible materials	Strong acids, strong oxidizing agents				
Hazardous decomposition	No dangerous decomposition products known.				
products					
Section 11: Toxicological Information					
Additional toxicological					
information:					
Carcinogenic categories					
IARC(International Agency for research on cancer)	Substance is not listed.				
NTP(National Toxicology	Substance is not listed.				
program)	S de Samuel 15 Mot Motod.				
OSHA-Ca(Occupational safety	Substance is not listed.				
& Health Administration) LD/LC50 values that are	8 mg/kg (mouse)				
relevant for classification:	3 mg/kg (mouse)				
	Section 12: Ecological Information				
General notes:	Water hazard class 1 (Self-assessment): slightly hazardous for water.				
	Do not allow undiluted product or large quantities of it to reach				
	ground water, water course or sewage system.				
	Section 13: Disposal Considerations				
Waste treatment methods	Must not be disposed of together with household garbage.				
Recommendation:	Do not allow Product to reach sewage system.				
Uncleaned packaging's: Recommendation:	Disposal must be made according to official regulations.				
recommendation.	Section 14: Transport Information				
	Section 14: Transport Information				
UN-Number DOT,IMDG,IATA	UN2811				
UN proper shipping name DOT,	Toxic solids, Organic, n.o.s (Lacosamide)				
IMDG,	Toxic SOLID, Organic. N.O.S. (Lacosamide)				
IATA	Toxic solid, organic, n.o.s (Lacosamide)				
Transport hazard class(es)	Not regulated				



DOT			
Packing group	III		
DOT IMDG IATA			

## **Section 15: Regulatory Information**

No further relevant information available

## **Section 16: Other Information**

Issue Date: 19-02-2022

Version: 00

**Further information** 

Revision date: New issue Revision note: New issue

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Annora Pharma Private Limited shall not be held liable for any damage resulting from handling or from contact with the above product. Annora Pharma Private Limited reserves the right to revise this SDS.